You just read:

BioLineRx Discloses Additional Data from Phase 2a COMBAT/KEYNOTE-202 Study in Pancreatic Cancer at ESMO 2018 Congress

News provided by

BioLineRx Ltd.

Oct 20, 2018, 13:00 ET